Sean joined Belharra in August 2022 as Senior Vice President, Head of Biology and a member of the Executive Committee. Sean has over 20 years’ experience in cancer biology and drug discovery. Before joining Belharra, he was at GNF/Novartis where he served as Executive Director of Cancer Therapeutics, responsible for the NIBR San Diego Oncology Drug Discovery portfolio. Prior to Novartis, he was at Eli Lilly for over a decade, serving in various roles and contributing to multiple cancer medicines and drug candidates. He started his industry career in 1999 at SGX Pharmaceuticals where he led the biology team. SGX was acquired by Eli Lilly in 2008.
Sean received his Ph.D. and Master’s degrees in Biochemistry at Cambridge University in the UK and did his post-doctoral research in Molecular Genetics at UCSD.